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ABSTRACT
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Objective: Dysregulated adipokine profiles contribute to the pathogenesis of diabetic cardiovascular complications. Endothelial cell (EC) dysfunction, a common pathological alteration in cardiovascular disorders, is exaggerated in diabetes. However, it is unclear whether and how dysregulated adipokines may contribute to
diabetic EC dysfunction.
Methods and results: Serum C1q/TNF-Related Protein 5 (CTRP5) were determined in control/diabetes patients,
and control/diabetic mice (high-fat diet, HFD). We observed for the first time that serum total CTRP5 was
increased, high molecular weight (HMW) form was decreased, but the globular form (gCTRP5) was significantly
increased in diabetic patients. These pathological alterations were reproduced in diabetic mice. To determine the
pathological significance of increased gCTRP5 in diabetes, in vivo, ex vivo and in vitro experiments were performed. Diabetic atherosclerosis and EC dysfunction were significantly attenuated by the in vivo administration
of CTRP5 neutralization antibody (CTRP5Ab). EC apoptosis was significantly increased in diabetic EC (isolated
from HFD animal aorta) or high glucose high lipid (HGHL) cultured HUVECs. These pathological alterations
were further potentiated by gCTRP5 and attenuated by CTRP5Ab. Pathway specific discovery-driven approach
revealed that Nox1 expression was one of the signaling molecules commonly activated by HFD, HGHL, and
gCTRP5. Treatment with CTRP5Ab reversed HFD-induced Nox1 upregulation. Finally, Nox1siRNA was used to
determine the causative role of Nox1 in gCTRP5 induced EC apoptosis in diabetes. Results showed that gCTRP5
activated the mitochondrial apoptotic signal of EC in diabetes, which was blocked by the silencing Nox1 gene.
Conclusion: We demonstrated for the first time that gCTRP5 is a novel molecule contributing to diabetic vascular
EC dysfunction through Nox1-mediated mitochondrial apoptosis, suggesting that interventions blocking gCTRP5
may protect diabetic EC function, ultimately attenuate diabetic cardiovascular complications.

1. Introduction
The prevalence of diabetes mellitus (DM) keeps dramatically rising
globally, and it is a major risk factor to cardiovascular disease [1].
Among diabetic vascular complications, atherosclerosis (AS) is a major
cause for ischemic heart disease, severe peripheral vascular disease, and
stroke [2,3], causing high morbidity and mortality in DM [4,5].
Diabetes is associated with marked fluctuations in the secretory
function of adipocytes, and increases the risk of vascular disease development. Dysfunctional adipocytes contribute directly and indirectly
to the development of vascular risk factors to vascular disease.

∗

Adipokine dysregulations appears to lead to AS in the diabetic setting
by influencing vascular endothelial cells (ECs), the first defense barrier
and vital defender to the vessel wall [6–8]. However, the causative
factor and the underlying mechanism is largely under-investigated.
We and other researchers demonstrated that C1q/tumor necrosis
factor-related proteins (CTRPs), a newly discovered secreted protein
family, play important role in the remaining homeostasis of vascular
system against diabetes and diabetic vasculopathy [9–11]. For Instance,
increased CTRP1 promotes endothelial barrier dysfunction under disturbed flow [12]. CTRP9 may exert vasorelaxation and anti-inflammatory effects [13,14]. CTRP3 may serve as a novel biomarker for
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Abbreviations
EC
CTRP5
HFD
HMW
gCTRP5
fCTRP5
HGHL
Nox
HUVEC
DM
AS
T2DM
CAS
CVD

HbA1c
FBG
TC
HDL-C
LDL-C
TG
TCH
ALT
AST
BMI
SBP
DBP
LDH
ROS
AUC

endothelial cells
C1q/TNF-Related Protein 5
high-fat diet
high molecular weight
globular CTRP5
full length of CTRP5
high glucose high lipid
NADPH oxidase
human umbilical vein endothelial cells
diabetes mellitus
atherosclerosis
type 2 diabetes mellitus
carotid atherosclerosis
cardiovascular disease

diabetic retinopathy (DR) preventing inflammatory response [15].
CTRP5 has been identified as a novel metabolic regulating cytokine
[16–18]. However, only few CTRP members have been investigated in
human studies and results are inconclusive. Due to the complexity of
various manifestations CTRPs, the biological function of CTRPs in
T2DM, particularly related to accelerated diabetic vascular endothelium dysfunction, is a critical area for research.
Therefore, the objectives of this study were: first, to determine the
key CTRPs members in the development of atherosclerosis in diabetes;
then to investigate how CTRPs are involved in diabetic vascular endothelium dysfunction in diabetic vasculopathy; and finally, to investigate the responsible underlying mechanisms.

glycosylated hemoglobin
fasting blood glucose
total cholesterol
high-density lipoprotein cholesterol
low-density lipoprotein cholesterol
triglycerides
total cholesterol
alanineamino transferease
aspartate amino transferease
Body mass index
systolic blood pressure
diastolic blood pressure
lactate dehydrogenase
reactive oxygen species
area under the curve

2.3. Biochemical measurements
We collected patient blood samples after overnight fasting. We
measured glycosylated hemoglobin (HbA1c), fasting blood glucose
(FBG), total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides
(TG), total cholesterol (TCH), alanineamino transferease (ALT) and
aspartate amino transferease (AST) with standard laboratory techniques
on a Hitachi 912 Analyzer (Roche Diagnostics, Germany). Body mass
index (BMI), systolic blood pressure (SBP), and diastolic blood pressure
(DBP) were measured. Insulin was assessed by commercially available
ELISA kit. We used the homeostasis model assessment of insulin resistance (HOMA-IR) to evaluate insulin function. The calculation formula is fasting blood glucose (mg/dL) × fasting blood insulin (μU/mL)
/405.

2. Material and methods
2.1. Participants

2.4. Enzyme-linked immunosorbent assay (ELISA)

The human study included 110 subjects aged between 18-80 yearsold who were diagnosed in the outpatient or inpatient departments of
the Second Affiliated Hospital of Shanxi Medical University between
January 2018 and June 2018. It included 40 healthy control subjects
(Control group), 35 type 2 diabetes mellitus (T2DM) patients without
carotid atherosclerosis (CAS) (T2DM group), and 35 T2DM with carotid
atherosclerosis (T2DM + CAS group). All study protocols were approved by the Ethics Committee of the Second Hospital of Shanxi
Medical University in accordance with the Declaration of Helsinki.
Written informed consents were obtained from all subjects prior to
study inclusion. To avoid confounding data, we excluded patients with
a history of stroke, type 1 diabetes mellitus (T1DM), valvar heart diseases, severe cardiovascular disease (CVD, cardiac function level at III
or IV by New York Heart Association standards), severe hepatic and
renal insufficiency, infectious diseases in the past two months, active
liver diseases, hemodialysis, malignancy, pregnancy or hyperthyroidism.

Serum CTRP5 levels were determined by commercial ELISA kit (Cat
#SK00594-06, Aviscera Bioscience) per manufacturer's instructions.
The level of TNF-α and IL-6 in cell culture supernatant were determined
by commercial ELISA kit (Cat #EK0525, #EK0410, Boster Biological
Technology) per manufacturer's instructions.
2.5. Type 2 diabetic mice model
All experiments of this study were performed in adherence to the
NIH Guidelines on the Use of Laboratory Animals and approved by the
Thomas Jefferson University and Shanxi Medical University Committee
on Animal Care. Apoe knockout mice (male Apoe-/- mice, 8–10 weeks
old) were utilized in this study. The mice were either fed the normal
diet (ND), or high-fat diet (HFD) (60% kcal fat, 20% kcal protein, 20%
kcal carbohydrate, Cat #D12492; Research Diets) for 12 weeks to induce type 2 diabetes, characterized by abnormal glucose
(FBG > 12 mmol/L) and insulin resistance. To detect glucose tolerance,
mice were intraperitoneally injected with D-glucose (1.5 g/kg) after
overnight fasting (12 h), and blood glucose was measured before injection (0 min) and after injection at 15, 30, 60 and 120 min. To assess
insulin tolerance, a single dose of Novolin R regular insulin (Novo
Nordisk) (0.5 units/kg) was intraperitoneally administered to the mice
after fasting for 4 h, and the blood glucose was measured at 0,15, 30,
60, and 120 min.
In order to investigate the function of CTRP5, CTRP5 neutralization
antibody (CTRP5Ab, 0.5 μg/g LifeSpan BioSciences) was applied to ND
or HFD mice.

2.2. Carotid ultrasonography
Carotid intima-middle thickness (cIMT) was defined as the distance
between the two parallel echogenic lines on the far wall of the artery in
the longitudinal plane image [19]. Carotid atherosclerotic plaques were
defined as a protrusion into the lumen, adding 50% to the thickness of
the surrounding intima-media or maximal thickness of 1.5 mm in the
carotid bifurcation or along the carotid arterial tree. We diagnosed
carotid atherosclerosis (CAS) in the presence of cIMT thickening
(cIMT≥1.0 mm) or atheromatous plaque presence.
2
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2.6. Arterial ring preparation and determination of vasorelaxation

premixed endothelial cell growth supplements (Cell Applications) per
manufacturer's instructions. The cells were used in 3-4 passages in all
experiments.
Primary mouse aortic endothelial cells obtained from ND, HFD and
HFD + CTRP5Ab group mice as described in a previous study [22].
Briefly, the aorta was harvested followed by isolating endothelial cells
with collagenase type II solution (2 mg/ml). The endothelial cells were
collected by centrifugation and suspended in the culture medium. When
the cells reached 80% confluence, they were collected and analyzed for
the following assay.

Mouse thoratic aortic vessel segments were harvested and cultured
in the Dulbecco's modification of eagle's medium (DMEM)containing
normal glucose/normal lipid in the presence and absence of globular
CTRP5/CTRP5 (gCTRP5/CTRP5, Aviscera Bioscience). After culturing
at 37 °C, 5% CO2 ambient incubator for 24 h, segments were suspended
upon stainless steel hooks, and placed in Krebs buffer solution (NaCl
118, KCl 4.75, CaCl2·2H2O 2.54, KH2PO4 1.19, MgSO4·7H2O 1.19,
NaHCO3 25, and glucose 10.0 mM) that is constantly permeated with
95% O2 and 5% CO2. Segments were first stretched to generate 2.5 mN
force, followed by 0.5 mN increments every 15 min until achieving
4 mN total force. After the vessel segments were balanced and prepared
for analysis, norepinephrine (NE, 10−7-10−4M) was administrated.
Endothelium-dependent vasorelaxation was determined by measuring
the cumulative response to acetylcholine (Ach, 10−7-10−4M). The endothelium-independent vasorelaxation was determined by administrated NaNO2 (10−4M) [13].

2.9. Real-time quantitative PCR
Total RNA from cells or tissues was extracted via a TRIzol reagent
(Invitrogen, Carlsbad, CA) per manufacturer instruction. Briefly, cDNA
was prepared from 1 μg total RNA using SuperScript III First-Strand
Synthesis System (Thermo Fisher Scientific). PCR was then performed
using the SYBR-Green Master mix (Thermo Fisher Scientific) in a
Quantstudio 5 Real-Time PCR machine (Applied Biosystems). Other
primers were purchased from Integrated DNA Technologies
(Supplements Table 1). 18S ribosomal RNA served as an internal control. PCR array panels (RT2 Profiler PCR Arrays, Qiagen) was performed per manufacturer's instructions. Data were normalized by the
standard comparative cycle threshold (CT) method.

2.7. Atherosclerotic lesion analysis
The entire aorta was isolated from ND or HFD mice with or without
treatment and fixed in 4% paraformaldehyde overnight. Staining was
performed with Sudan IV (Sigma) according to the previous study [20].
Briefly, after fixation, the vessels were stained with Sudan IV dye for
3 min twice. Non-specific staining was then performed with 80%
ethanol for 2.5 min. The images were collected by Olympus DP72 with
Desense Pro software to analyze the area of red plaques.

2.10. Western blot analysis
Western blot assay was conducted as described in the previous study
[13]. Briefly, cells or tissues were harvested and 50 μg total proteins per
sample were separated by gel electrophoresis, transferred to a polyvinylidene fluoride membrane. The membrane was incubated overnight
with primary antibodies (Supplements Table 2) at 4 °C, followed by
secondary HRP-conjugated antibody (anti-mouse or anti-rabbit antibody, Cell Signaling) at room temperature for 2 h, visualized by enhanced chemiluminescence (Thermo Fisher Scientific) and captured
images on ChemiDoc MP imaging system (Bio-rad). The results of
Western blot were quantified by densitometry (Image Lab).

2.8. Cell cultures
Human umbilical vein endothelial cells (HUVECs, Cell Applications)
were randomized to receive corresponding intervention after reaching
80% confluence. The normal glucose/normal lipid contains 5.5 mM Dglucose in DMEM medium, and the high glucose/high lipids (HGHL)
contains 25 mM D-glucose and 200 μM palmitates in DMEM medium
[21]. Both culture medium comprises 10% fetal bovine serum (FBS) and
Table 1
General characteristics of study subjects.
Variable

Control (n = 40)

T2DM (n = 35)

T2DM + CAS (n = 35)

P

Sex (M/F)
Smoker (Y/N)
Drinker (Y/N)
Age (year)
BMI (kg/m2)
SBP (mmHg)
DBP (mmHg)
FBG (mmol/L)
Insulin (μU/ml)
HOMA-IR
HbA1c (%)
TG (mmol/L)
TC (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
ALT (U/L)
AST (U/L)
ESR (mm/h)
hsCRP (mg/L)
CTRP5 (ng/ml)

19/21
6/34
5/35
50.73 ± 11.18
23.29 ± 2.44
118.28 ± 10.61
73.50 ± 10.00
4.80 ± 0.48
7.75 ± 2.08
1.66 ± 0.47
4.90 ± 0.58
1.46 ± 0.94
4.17 ± 1.19
2.08 ± 0.59
1.40 ± 0.29
13.25 ± 6.75
18.80 ± 5.68
13.00 ± 10.00
1.95 ± 1.60
100.21 ± 37.94

19/16
9/26
7/28
50.57 ± 9.89
23.95 ± 3.44
128.80 ± 12.03**
78.00 ± 10.00
7.77 ± 2.29**
10.40 ± 3.60**
3.55 ± 1.91**
8.00 ± 3.10**
1.48 ± 1.42
4.94 ± 1.22**
2.64 ± 1.12*
1.16 ± 0.29**
24.30 ± 23.6**
22.10 ± 11.00
14.00 ± 8.00
2.31 ± 2.60
168.48 ± 39.25**

19/16
13/22
8/27
55.69 ± 10.56*#
25.20 ± 3.17**
138.57 ± 14.83**##
71.00 ± 12.00
7.44 ± 3.01**
10.20 ± 3.20**
3.56 ± 1.58**
7.90 ± 2.10**
2.01 ± 1.65*
4.93 ± 1.47*
2.89 ± 1.03**
1.04 ± 0.22**
17.40 ± 11.90*
20.20 ± 6.60
11.00 ± 11.00
2.71 ± 3.64
230.93 ± 34.97**##

0.791
0.090
0.482
0.072
< 0.001
< 0.001
0.415
< 0.001
< 0.001
< 0.001
< 0.001
0.012
0.004
< 0.001
< 0.001
< 0.001
0.066
0.879
0.201
< 0.001

*P < 0.05, **P < 0.01 Comparison with Control.
#
P < 0.05.
##
P < 0.01 Comparison with T2DM.
Data are mean ± SD. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood-glucose; HOMA-IR, homeostasis model
insulin resistance index; HbA1c, glycated hemoglobin A1c; TG, riglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartic aminotransferase; ESR, erythrocyte sedimentation rate; hsCRP, highsensitive C-reactive protein;
CTRP5, C1q/TNF-related protein 5.
3
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2.13. TUNEL staining

Table 2
Correlation between T2DM + CAS and laboratory characteristics Univariate
logistics regression analysis.
Variable

OR

OR 95%CI

P-value

Sex (M/F)
Age (year)
Smoker (Y/N)
Drinker (Y/N)
BMI (kg/m2)
SBP (mmHg)
DBP (mmHg)
FBG (mmol/L)
Insulin (μU/ml)
HOMA-IR
HbA1c (%)
TG (mmol/L)
TC (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
ALT (U/L)
AST (U/L)
ESR (mm/h)
CRP (mg/L)
CTRP5 (ng/ml)

1
1.051
1.707
1.185
1.197
1.056
0.973
1.012
0.889
0.968
0.881
1.218
0.900
1.466
0.159
0.965
0.954
1.014
1.014
1.048

0.390–2.561
1.001–1.104
0.614–4.744
0.378–3.720
1.009–1.420
1.015–1.098
0.923–1.026
0.842–1.215
0.709–1.115
0.713–1.314
0.661–1.174
0.850–1.745
0.558–1.452
0.755–2.847
0.023–1.091
0.930–1.001
0.904–1.008
0.960–1.070
0.882–1.165
1.026–1.071

1
0.045
0.305
0.771
0.039
0.006
0.314
0.902
0.309
0.834
0.387
0.282
0.666
0.259
0.061
0.060
0.092
0.619
0.843
< 0.001

EC apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining via Roche In
Situ Cell Death Detection Kit (Sigma) per manufacturer's protocol. The
nuclei were stained with DAPI. The index of apoptosis was determined
by the number of TUNEL positive nuclei/the total nuclei in the field.
The images were acquired by Olympus BX51 Fluorescence Microscope,
and analyzed by Image J (NIH) software.
2.14. Small interfering RNA transfection
siRNA duplex oligonucleotides were designed for Nox1 target sequences, silencing Nox1 gene expression. Nox1-siRNA and non-target
control siRNA were purchased from Santa Cruz. When HUVEC reached
80% confluence, cells were transfected with siRNA via Attractene
Transfection Reagent (Qiagen) per manufacturer protocol (final siRNA
concentration 100 nM). Cells were then challenged by different interventions in experiments.
2.15. Statistical analysis
Data with normal distribution are expressed as mean ± SD.
Skewed distributed variables are expressed with median ±
interquartile ranges (IQR). For continuous variables, normal distribution was evaluated by the Shapiro-Wilk test. The unpaired Student t-test
was performed for analysis of differences between two groups. For
multiple groups, one-way ANOVA was carried out. For non-normal
distribution data, differences between groups were tested by the MannWhitney U test. The differences in the distribution of categorical variables were evaluated by Chi-square test. The effects of different variables were calculated using univariate logistics regression analysis. We
built a multivariate model among the significant variables noted by
univariate analysis to determine potential markers for T2DM with CAS.
All statistical analyses were performed with SPSS 25 or Graph Pad
Prism 8. P values < 0.05 were considered significant.

Values were determined by using univariate logistics regression analysis. BMI,
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
FBG, fasting blood-glucose; HOMA-IR, homeostasis model insulin resistance
index; HbA1c, glycated hemoglobin A1c; TG, riglycerides; TC, total cholesterol;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; ALT, alanine aminotransferase; AST, aspartic aminotransferase;
ESR, erythrocyte sedimentation rate; hsCRP, highsensitive C-reactive protein;
CTRP5, C1q/TNF-related protein 5.

Mouse and human serum were used for Non-reducing Western
blotting. Serum samples were run on 4–20% gradient gel without βmercaptoethanol and SDS additives.
2.11. Cell viability assay and lactate dehydrogenase (LDH) assay
Cell viability was determined using the MTT [3-(4,5-dimethythiazol-2-yl) 2,5-diphenyltetrazolium bromide] assay per the
previous study [23]. In brief, HUVECs were exposed to vehicle, HGHL,
and CTRP5 (gCTRP5, full-length CTRP5 [fCTRP5]) (Aviscera
Bioscience) at different concentrations with/without the present of
HGHL for 24 h. Then, the 0.5 mg/ml MTT was applied and the absorbance at 570 nm was measured by SpectraMax M5 microplate reader
(Molecular Devices).
HUVECs were exposed to vehicle, gCTRP5, or HGHL with or
without gCTRP5 for 24 h. The cells were harvested and cell medium
was collected for LDH assay as performed previously [23]. Briefly, at
the end of the observation period, conditioned media, and the cells
were collected. LDH activity was determined using pre-prepared reaction mixture solution. The absorbance of samples at 490 nm was
measured by the SpectraMax M5 microplate reader (Molecular Devices). The percentage of LDH release was calculated as follows: (A-B)/
(C-B) × 100, where A is LDH activity in conditioned media, B is LDH
activity in culture media (without cells), and C is LDH activity in cell
lysates.

3. Results
3.1. Serum circulatory CTRP5 may serve as an independent predictor in
T2DM combined with CAS
A total of 110 subjects were enrolled in this study. Demographic
data, baseline clinical and biochemical characteristics are presented in
Table 1. Statistical analysis showed that the levels of CTRP5, SBP, FBG,
insulin, HOMA-IR, HbA1c, TC, LDL-C, ALT were increased, and the
levels of HDL-C were decreased in the T2DM group compared to the
control group. In the T2DM combined with CAS group, CTRP5 level was
further increased compared to the T2DM group without CAS (Table 1),
which was confirmed by Western blot assay (Fig 1A–1D). Univariate
logistics regression analysis indicated that CAS combined with T2DM
was positively correlated with age, BMI, SBP and CTRP5 (Table 2).
To reveal the relationship between CTRP5 and T2DM with CAS, we
built a multivariate model among the significant variables noted by
univariate analysis to determine a potential marker for T2DM with CAS.
Notably, results showed that CTRP5 was an independent predictor for
CAS in T2DM (hazard ratio, 1.053; 95% CI, 1.026–1.080; p < 0.001)
(Table 3). In addition, the ROC curve indicated that CTRP5 may serve
as a diagnostic marker for CAS combined with T2DM as the area under
the curve (AUC) was 0.885 (95% CI, 0.806–0.964; p < 0.001)
(Table 4, Fig. 1E).

2.12. Detection of reactive oxygen species (ROS) production
The ROS production was assessed by CellROX Deep Red oxidative
stress indicator (Invitrogen), which is a fluorogenic dye specifically
targeted to ROS in live cells. After treatment, HUVEC were stained with
ROS sensor (5 μM) and Hoechst 33342 Solution (1 μg/mL, Thermo
Scientific) for nuclei. Then, the cells were washed with PBS. The images
were acquired via an Olympus BX51 Fluorescence Microscope and
analyzed by Image J software (NIH).

3.2. Globular CTRP5 (gCTRP5) increased in diabetic condition
CTRP5 monomer forms complex aggregates that circulate in the
body as high, medium, and low-molecular-weight forms [24]. To
4
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Fig. 1. Serum CTRP5 profile was altered in
T2DM. A Human serum CTRP5 monomer and
gCTRP5 were detected by Western blot. B Human
serum HMW CTRP5 was detected by non-reducing
Western blot. C Quantification of Western blot from
human serum CTRP5 monomer and gCTRP5. D
Quantification of non-reducing Western blot from
human serum HMW CTRP5. n = 5. **p < 0.01 vs.
Control. E ROC curve analysis revealed that CTRP5
distinguishes
patients
with
and
without
T2DM + CAS. F Mouse serum CTRP5 monomer and
gCTRP5 were detected by Western blot. G Mouse
serum HMW CTRP5 was detected by non-reducing
Western blot. H Quantification of Western blot for
mouse serum CTRP5 monomer and gCTRP5. I
Quantification of non-reducing Western blot for
mouse serum HMW CTRP5. n = 10. **p < 0.01 vs.
ND. J CTRP5 distribution was analyzed by Realtime quantitative PCR. Results were expressed as
mean ± SD. n = 3. **p < 0.01 vs. CTRP5, C1q/
TNF-Related Protein 5; gCTRP5, globular CTRP5.
T2DM, type 2 diabetes; HMW, high molecule
weight; CON, Control; ND, normal diet; HFD, highfat diet.

molecular weight (HMW) (Fig. 1B, 1D) but a significantly increased
monomer and globular form of CTRP5 (Fig. 1A, down bands) in T2DM
compared with the control group.
To further verify these findings in animals, type 2 diabetic mice
models were established. The characteristics of HFD mice demonstrated
an effective diabetic model with increased body weight, abnormal
glucose tolerance and insulin resistance (Supplementary Figs. 1A–1D).
Consistent with the patient's analysis, the CTRP5's profile in animal
serum showed a similar pattern as that of human serum (Fig. 1F–1I).
Quantitative real-time PCR analysis was explored to clarify CTRP5
tissue distribution. The results demonstrated that although CTRP5 was
widely expressed in multiple tissues, the level of CTRP5 in visceral
adipose tissue, perivascular adipose tissue and aorta were ranked on the
top three most significantly changed in HFD mice compared with the
ND mice, suggesting that CTRP5 may function in the physiological and
pathological process of vascular system. Interestingly, the level of
CTRP5 in the lung, heart, and spleen was down-regulated in HFD mice
compared with the ND mice (Fig. 1J).

Table 3
Multivariate logistics regression analysis.
Variable

OR

OR 95%CI

P-value

Age (year)
SBP (mmHg)
BMI (kg/m2)
CTRP5 (ng/ml)

1.025
1.047
0.846
1.053

0.955–1.100
0.986–1.113
0.627–1.140
1.026–1.080

0.499
0.135
0.272
< 0.001

Values were determined by using multivariate logistics regression analysis.
CTRP5, C1q/TNF-related protein 5.
Table 4
ROC curves, for T2DM + CAS diagnosis, by circulating CTRP5 level.
Variable

AUC

SE

P-value

95%CI

CTRP5 (ng/ml)

0.885

0.040

< 0.001

0.806–0.964

CTRP5, C1q/TNF-related protein 5.

further clarify the alteration of CTRP5's profile in the setting of diabetes, human serum samples were analyzed with reducing/non-reducing Western blotting assay. The results demonstrated an increased
total CTRP5 (Fig. 1A, up bands and Fig. 1C), a decreased high

3.3. CTRP5 antibody attenuated diabetic vascular injury and gCTRP5
promoted endothelial dysfunction
Next, to explore CTRP5 biological function in the setting of diabetes
5
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and to determine whether it induces diabetic endothelial dysfunction,
HFD mice were subjected to CTRP5 neutralization antibody (CTRP5Ab)
administration. Atherosclerotic plaques were assessed. The results
showed that the area of atherosclerotic plaque in the aorta of Apoe-/mice increased significantly after HFD 12 weeks, while CTRP5Ab
treated group markedly reduced the lesions (Fig. 2A, 2B).
Then, to investigate the role of CTRP5 in endothelial dysfunction,
the aortic segments from ND, HFD, and CTRP5Ab treated HFD mice
were analyzed. The vasorelaxation impairment was pronounced in HFD
mice compared to ND mice. Notably, the delivery of CTRP5Ab manifestly ameliorated the decline of vasorelaxation caused by HFD (Fig. 2C,
2D).
To identify which form of CTRP5 (monomer CTRP5 or gCTRP5) was
responsible for the endothelial dysfunction, isolated aortic segments
from ND Apoe-/- mice were incubated in vehicle or gCTRP5/CTRP5
with or without HGHL for 24 h ex vivo. Administrating acetylcholine

(an endothelium-dependent vasodilator) resulted in concentration-dependent vasorelaxation in ND mice, while the vasorelaxation was significantly blunted in HGHL treated vessels. Moreover, relaxation was
further suppressed by gCTRP5 addition (Fig. 2E, 2F). Importantly, vasorelaxation response to acifified NaNO2, an endothelium-independent
NO donor, was not impaired in HGHL-incubated aortic rings with/
without gCTRP9 (Fig. 2G, 2H). Surprisingly, monomer CTRP5 did not
show any additional suppressive effect on HGHL-induced endothelial
dysfunction (data not shown). Taken together, these results demonstrated that gCTRP9 exacerbates HGHL-induced endothelial dysfunction without affecting smooth muscle function, suggesting that elevated
gCTRP9 in diabetic individuals may contribute to endothelial dysfunction.

Fig. 2. CTRP5 antibody attenuated vascular injury and gCTRP5 induced diabetic endothelial
dysfunction. A Representative figures of the
atherosclerotic lesion. CTRP5Ab treatment reduced
atherosclerosis lesion area compared to HFD with
vehicle. B Bar graphs represented the analysis results of the lesion area. **p < 0.01 vs. ND.
##
p < 0.01 vs. HFD. n = 10. C The Aortic segment
relaxation was significantly restored in the
HFD + CTRP5Ab group compared to the segments
from the HFD group with vehicle. D Analysis of
relaxation of the aortic segment after Acetylcholine
(ACh) was introduced in ND, HFD, and HFD + ACh
groups. E gCTRP5 (1 μg/ml) induced endothelial
dysfunction with/without HGHL (high glucose:
25.5 mmol/L; high palmitate: 200 μmol/L), which
was evaluated by vessel ring assay. F Analysis of
vessel ring relaxation of the aortic segment. G
gCTRP5 (1 μg/ml) did not cause smooth muscle
dysfunction, as the response to acidified NaNO2, an
endothelium-independent vasodilator was unchanged. H Analysis of vessel ring relaxation of the
aortic segment. **p < 0.01, ##p < 0.01 vs. respective control. In aortic vascular rings experiments, each mouse aorta generated 2-3 rings, n = 8
rings/group. Results are expressed as mean ± SD.
ND, normal diet; HFD, high-fat diet; ACh,
Acetylcholine; Ab, antibody; ND, normal diet; HFD,
high-fat diet.
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3.4. gCTRP5 aggravated vascular endothelial apoptosis in T2DM

Next, to evaluate if gCTRP5 aggravates the apoptosis of vascular EC
in T2DM, the TUNEL assay was explored on endothelial cells isolated
from ND and HFD mice with or without CTRP5Ab treatment. The
TUNEL positive cells were significantly increased in aortic EC isolated
from HFD mice than ND mice, and CTRP5Ab significantly relieved the
increased apoptotic level in treated HFD animal group (Fig. 3D, 3E).
Thirdly, the apoptotic signal alteration was assessed ex vivo. The
cleaved caspase 3 were markedly increased in aortic endothelial cells
isolated from HFD mice than the cells from ND mice, and this increase
was markedly alleviated in CTRP5Ab treated mice group (Fig. 3F, 3G).
Additionally, cleaved caspase 3 was markedly increased after HUVECs
were challenged for 24 h by HGHL, and the increase was exaggerated in
the presence of gCTRP5 (Fig. 3H, 3I). Collectively, gCTRP5 contributes
to the enhanced EC apoptosis in the setting of diabetes.

To identify the mechanism responsible for gCTRP5-inducedendothelial dysfunction, we designed three serial experiments to
evaluate the effect of gCTRP5 on the function of endothelial cells. First,
to obtain direct evidence, HUVECs were incubated for 24 h with various
doses of gCTRP5 in the presence or absence of HGHL.Then cell viability
was evaluated by MTT cell proliferation assay, and cell toxic assay was
assessed by LDH measurement. The vitality of HUVECs was reduced by
HGHL in a dose-dependent manner (Supplementary Fig. 2). Of note, the
viability of EC was significantly reduced by 1 μg/mL gCTRP5, and it
was further reduced in the presence of HGHL. However, it showed no
difference between the treatments of 5 μg/mL gCTRP5 and 10 μg/mL
gCTRP5 (Fig. 3A). Interestingly, the treatment of the full length of
CTRP5 (fCTRP5, 10 μg/mL) did not aggravate the decrease of EC vitality induced by HGHL (Fig. 3B). Consistently, LDH results showed that
gCTRP5 (1 μg/mL) markedly induced the cytotoxicity of endothelial
cells, especially when co-treated with HGHL (Fig. 3C).

Fig. 3. gCTRP5 aggravated diabetic
vascular EC apoptosis. A HUVEC viability was evaluated by MTT assay.
HUVEC were either treated with vehicle or different doses of gCTRP5
(0–5 μg /mL) in the presence or absence of HGHL. n = 8. **p < 0.01,
*p < 0.05 vs. vehicle. #p < 0.05,
##
p < 0.01 vs. HGHL. B HUVEC viability was evaluated with MTT assay
after the cells were treated with vehicle, HGHL or HGHL combined with
gCTRP5 (1 μg/mL) or fCTRP5 (10 μg/
mL). n = 8. **p < 0.01 vs. vehicle.
##
p < 0.01 vs. HGHL. C HUVEC cytotoxicity was determined by LDH
assay after the cells were incubated
with vehicle or gCTRP5 (1 μg/mL) with
or without HGHL. n = 8. **p < 0.01
vs. vehicle. ##p < 0.01 vs. HGHL. D
Aortic EC's apoptosis was determined
by TUNEL staining. Aortic endothelial
cells were isolated from ND, HFD and
HFD + CTRP5Ab mice. Green, apoptosis positive cells. Blue, DAPI stained
nuclei. E The number of TUNEL positive
nuclei/the
total
nuclei.
**p < 0.01 vs. vehicle. ##p < 0.01
vs. HGHL. F Western blot was performed to analyze protein expression of
cleaved caspase 3 and caspase 3 in
aortic ECs from ND, HFD and
HFD + CTRP5Ab group mice. G
Quantification of the Western blot results. n = 10. **p < 0.01 vs. ND.
##
p < 0.01 vs. HFD. H Western blot
was performed to analyze protein expression of cleaved caspase 3 and caspase 3 in HUVECs after incubated in
vehicle or gCTRP5 (1 μg/mL) with or
without
HGHL
for
24
h.
I
Quantification of the western blot results. Data were expressed as
mean ± SD. n = 5. **p < 0.01,
*p < 0.05 vs. vehicle. ##p < 0.01 vs.
HGHL. gCTRP5, globular CTRP5;
fCTRP5, full length CTRP5; HGHL, high
glucose and high lipid; HUVEC, human
umbilical vein cells; ND, normal diet;
HFD, high-fat diet.
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3.5. gCTRP5 upregulated the inflammatory signals including Nox1 in
diabetic vascular EC

gCTRP5 and HGHL (Fig. 4A) and so did the level of TNF-α and IL-6 in
the supernatants (Fig. 4D, 4E). Hence, gCTRP5 stimulation promoted
oxidative stress and inflammatory response in the setting of diabetes;
furthermore, the CTRP5 neutral antibody reduced the amplitude of
inflammatory responses as demonstrated by the experiments described
above.

We next investigated the underlying molecular mechanism of
gCTRP5 induced endothelial dysfunction. PCR array panels including
oxidative stress signals, an inflammation panel, and endoplasmic reticulum stress (ERS) panel were assessed to screen the genes responsible
for gCTRP5-exacerbated HUVECs dysfunction. Among the screened
genes, the inflammation and oxidative stress related genes were ranked
on the top (Fig. 4A). The most significantly changed gene after gCTRP5
treatment was oxidative stress related gene Nox1 (Fig. 4B and 4C),
which is a subtype of NADPH oxidase (NOX) and is the main source of
ROS production in the vascular system exposed to high glucose [25].
Hence, the role of gCTRP5 in the regulation of Nox1 was further explored both ex vivo and in vitro. Nox1 expression was significantly
increased in HFD mouse aortic ECs compared to that of ND mice, and
this increase was clearly relieved in CTRP5Ab induced group (Fig. 4F,
4G). Meanwhile, we found that the Nox1 expression was significantly
increased after HUVECs were challenged for 24 h with HGHL, and
gCTRP5 further elevated the Nox1 level when co-treatment with HGHL
(Fig. 4H, 4I). Additionally, the inflammation-related gene TNF-α and
IL-6 presented the similar upregulatory pattern when exposed to

3.6. gCTRP5 exacerbated apoptosis of EC in T2DM via Nox1/
mitochondrial pathway
Since gCTRP5 may regulate the ROS generation and since mitochondria not only regulates the production of ATP and ROS but also
plays an important role in cell apoptosis [26,27], we hypothesized that
gCTRP5 induced endothelial dysfunction may be related to the mitochondrial apoptotic pathway. The intensity of fluorescence indicated
that gCTRP5 significantly aggravated ROS generation when co-incubated with HGHL (Fig. 5A, 5B). Next, we assessed the gCTRP5's role
in apoptotic signals in vivo and in vitro. The caspase 9 activation and
Bcl2/Bax level were evaluated, which indicates whether the mitochondrial apoptotic pathway was involved. Compared with the ND
group, the caspase 9 activation and Bax level of aortic EC isolated from
HFD mice were significantly augmented, while Bcl2 expression was
Fig. 4. gCTRP5 upregulated Nox1
expression in vascular EC in T2DM. A
Gene array assay of endothelial cell
biology in HUVEC which were treated
with HGHL or gCTRP5 (1 μg/mL) with
HGHL condition for 24 h n = 3.
**p < 0.01, *p < 0.05 vs HGHL. B
Quantitative Real time PCR verified
mRNA expression of target genes.
n = 6. ##p < 0.01 vs. HGHL. C
Quantitative Real time PCR verified
mRNA expression of Nox1 genes.
n = 6. **p < 0.01, *p < 0.05 vs.
vehicle. ##p < 0.01 vs. HGHL. D TNFα level in cell culture supernatant was
detected by ELISA. E IL-6 level in cell
culture supernatant was detected by
ELISA. n = 5. **p < 0.01, *p < 0.05
vs. vehicle. ##p < 0.01, #p < 0.05 vs.
HGHL. F Western blot analysis of Nox1
protein expression in aortic ECs from
ND, HFD and HFD + CTRP5Ab mice. G
Quantification of the western blot results. n = 6. **p < 0.01, *p < 0.05
vs. ND. ##p < 0.01 vs. HFD. H
Western blot analysis of Nox1 protein
expression in HUVEC after incubation
with gCTRP5 (1 μg/mL) with or
without
HGHL
for
24
h.
I
Quantification of the Western blot results. n = 5. **p < 0.01, *p < 0.05
vs. vehicle. ##p < 0.01 vs. HGHL.
Data were expressed as mean ± SD.
gCTRP5, globular CTRP5; HGHL, high
glucose and high lipid; HUVEC, human
umbilical vein cells; ND, normal diet;
HFD, high-fat diet.
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Fig. 5. gCTRP5 aggravated diabetic vascular EC
apoptosis via the mitochondrial pathway. A
Representative fluorescent images showed mitochondrial ROS productions in HUVEC which were
incubated with gCTRP5 (1 μg/mL) with or without
HGHL. B Bar graph of quantification for
Fluorescence (FL) density. n = 5. **p < 0.01 vs.
vehicle. ##p < 0.01 vs. HGHL. C Western blot
analysis of protein expression of Bax, Bcl2, cleaved
caspase 9 and caspase 9 in aortic endothelial cells
isolated from ND, HFD, and HFD + CTRP5Ab mice.
D, E and F Quantification of the Western blot results. n = 6–10. **p < 0.01 vs. ND. ##p < 0.01,
#
p < 0.05 vs. HFD. G Western blot presented
protein expression of cleaved Bax, Bcl2, cleaved
caspase 9 and caspase 9 in HUVECs after the treatment of gCTRP5 (1 μg/mL) with or without HGHL
for 24 h. H, I and J Quantification of the Western
blot results. n = 5. **p < 0.01, *p < 0.05 vs.
vehicle. ##p < 0.01 vs. HGHL. Data are expressed
as mean ± SD. gCTRP5, globular CTRP5; ROS,
reactive oxygen species; HGHL, high glucose and
high lipid; HUVEC, human umbilical vein cells; ND,
normal diet; HFD, high-fat diet.

markedly suppressed. These pathologic alterations were partially reversed in CTRP5Ab administrated mice (Fig. 5C–5F). However, the
evaluation on caspase 8 (Cytosolic apoptosis signal) did not show the
statistical difference. Meanwhile, gCTRP5 significantly increased the
cleaved caspase 9 and Bax level in HGHL-cultued HUVECs, and supressed Bcl2 level (Fig. 5G–5J). These above results suggested that
gCTRP5 aggravated HGHL-induced endothelial apoptosis through the
oxidative stress-induced, mitochondrial-mediated cell death pathway.
To investigate the causative role of Nox1 in gCTRP5 induced mitochondrial apoptosis in endothelial cells, Nox1 specific small interfering RNA (Nox1 siRNA) and negative control siRNA (NCsiRNA) was
utilized. As depicted in Fig. 6A–6F, after successfully knocked down
Nox1 by siRNA (Fig. 6B) in HUVEC, gCTRP5 (1 μg/mL) failed to facilitate the HGHL-induced increase in Bax, cleaved caspase 9, and
cleaved caspase 3 level. It also abolished gCTRP5-induced Bcl2 reduction. In addition, Bax expression levels and caspase 9 and caspase 3
activation declined in the Nox1 knockdown group compared to the
HGHL group with control siRNA (HGHL + NCsiRNA), and the Bcl2
expression was preserved (Fig. 6C–6F). Consistently, mitochondrial
ROS specific staining demonstrated that Nox1 deficiency alleviated
gCTRP5-aggravated mitochondrial apoptosis in HGHL cultured EC

(Fig. 6G, 6H). Taken together, these results indicate that gCTRP5 exacerbates EC apoptosis in T2DM via the Nox1/mitochondrial cell death
pathway.
4. Discussion
In the current study, we first report that increased circulating
CTRP5 may serve as a novel diagnostic marker and an independent
predictor for diabetes with CAS. We also report that the increased
globular form of CTRP5 contributing to accelerated endothelial dysfunction in the setting of diabetes. Additionally, we found that gCTRP5
contributes to endothelial cell apoptosis by promoting an oxidative
stress induced and Nox-1 mediated mitochondrial cell death pathway.
and.CAS is the pathological basis of diabetic macrovascular complications and it can evaluate the severity of macroangiopathy in T2DM.
Hence, identification of a predictor of diabetic macrovascular complications (such as CAS) is greatly in need. CTRP5 was identified by
multivariate logistics regression analysis followed by the ROC curve
assay. The results indicated that CTRP5 may serve as a predictor for
diabetic macrovascular complications in T2DM. In addition to our report, accumulated data showed that increased CTRP5 can predict
9
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Fig. 6. gCTRP5 disrupted mitochondrial signals
via augmented Nox1 level in EC. A Western blot
examined the expression of Nox1, Bax, Bcl2 proteins
and the activity of caspase3, caspase9 in HUVEC
which was treated with HGHL or HGHL + gCTRP5
after NCsiRNA or Nox1siRNA transfection. B, C, D,
E and F Quantification of Western blot results.
n = 5. **p < 0.01 vs. HGHL + NCsiRNA.
##
p < 0.01 vs. HGHL + gCTRP5+NCsiRNA. G
Representative fluorescent images exhibited mitochondrial ROS productions in HUVEC which
treated with HGHL + gCTRP5 for 24 h after transfection of NCsiRNA or Nox1siRNA. H Fluorescence
(FL) density quantification for ROS generation.
##
n
=
5.
p
<
0.01
vs.
HGHL + gCTRP5+NCsiRNA. Data were expressed
as mean ± SD. gCTRP5, globular CTRP5; ROS,
reactive oxygen species; HGHL, high glucose and
high lipid; HUVEC, human umbilical vein cells;
NCsiRNA, negative control siRNA; Nox1siRNA,
NADPH oxidase1 specific siRNA.

inflammatory response in COPD and metabolic syndrome, and is associated with in-stent restenosis [28–30].
APN exists in multiple oligomers: trimers, hexamers, and HMW,
each with distinct biological activities [31]. Globular APN (gAPN),
known as the product of full-length adiponectin (fAPN) cleaved by
leukocyte elastase secreted from activated monocytes and/or neutrophils, has also been found in human plasma [32,33]. Like APN,
CTRP5 proteins form trimers as their basic structural units and further
assemble into higher-order oligomeric complexes [24]. However, what
and why the forms of CTRP5 in diabetes change, and whether there
exist functional globular fragments need to be clarified. In the current
study, we first demonstrated that total CTRP5 was increased in T2DM
patients serum, HMW form was decreased, but full-length CTRP5 and
gCTRP5 were significantly increased. Consistent with the clinical results, the animal experiments suggested that the cleaved CTRP5 may
play a role in the development of CAS.
Moreover, both LDH and MTT results showed that gCTRP5, not

fCTRP5, reduced EC viability, strongly suggesting that gCTRP5 may be
a pathologic response to the setting of T2DM and may play a central
role in it.
Several studies have suggested that members of CTRPs may be associated with endothelial function [13–15] with unclear mechanisms.
Our data from ex vivo and in vivo experiments demonstrated that
gCTRP5 resulted in direct endothelial dysfunction and aggravated
HGHL-induced endothelial dysfunction. Besides hyperglycemia, free
fatty acid levels have been found to be notably increased in diabetic
patients and animals, of which palmitic acid is the predominant component. Hence, HG alone could not mimic the diabetic microenvironment completely, especially in the case of T2DM. Therefore, combination of HG and 200 μM palmitates were used to mimic T2DM [21]. In
addition, CTRP5Ab effectively alleviates AS plaque formation in Apoe-/HFD mice and ameliorates mitochondrial apoptotic signals, suggesting
circulating gCTRP5 may be one of the causes of diabetic macrovascular
complications in T2DM.
10
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EC monolayers provides a barrier by constituting the luminal surface of all blood vessels [34]. Endothelial cell apoptosis is responsible
for endothelial dysfunction that results in endothelial barrier destruction. The emerging evidence showed that mitochondrial dysfunction
are the key in the development of endothelial injury and diabetic vasculopathy [35]. Our second discovery was that HFD-induced caspase 3
activation was alleviated by CTRP5Ab, revealing that CTRP5 contributes to endothelial apoptosis in T2DM. We selected 200 μM as the
high palmitate concentration in our in vitro experiments based on the
lipid range of clinical hyperlipidemia. We further confirmed that
gCTRP5 aggravates HGHL-induced EC apoptosis, indicating gCTRP5 is
one of the mechanisms responsible for increased susceptibility to vascular disease in diabetic individual than normal people.
Finally, we demonstrated that Nox 1 is the key molecule to promote
gCTRP5 associated EC injury. We screened multiples genes to identify
potential mechanisms responsible for gCTRP5 regulatory pathways in
endothelial cells. Nox1, a subtype of NADPH oxidase (NOX) draw our
attention. Excess production of ROS plays a major role in diabetes-accelerated AS [36,37]. Nox has been implicated as the major source of
ROS generation in the vessel in response to diabetes [25]. Among all
Nox isoforms (Nox1, Nox2, Nox4, and Nox5) involved in the vasculature [38–40], we found that gCTRP5 significantly upregulated
Nox1expression. These findings were confirmed in in vivo and ex vivo
diabetic models. CTRP5Ab ameliorated Nox1 protein increase in HFD.
gCTRP5 could aggravate HGHL-induced upregulation of Nox1 protein
expression in vitro. Hence, we showed that Nox1 is involved in gCTRP5induced endothelial apoptosis in T2DM. Given mitochondrial dysfunction is one of the major causes of vascular injury in T2DM [35,41–43],
we investigated the regulatory effect of gCTRP5 on mitochondria. Our
data showed that CTRP5Ab administration alleviated caspase 9 overactivation and restored Bcl2/Bax expression in HFD. These results indicate that gCTRP5 leads to EC apoptosis through the mitochondrial
pathway in the diabetic setting.
Our study has several limitations. Firstly, the gCTRP5 quantification
was based on Western blot assay because gCTRP5 ELISA assay is not
currently available. Although Western is sensitive (with detective sensitivity lower than 10 ng) it is not the best quantitative measurement.
Secondly, the local concentration of gCTRP5 (perivascular area) remains completely unknown, although it is likely higher than that in
circulation. Hence, more research is needed to identify the proper dose
of gCTRP5. Thirdly, we utilized male mice in our study because female
mice have superior resistance to macrovascular atherosclerosis than
males in response to high fat diet due to the enhanced angiogenesis
[44]. Moreover, male mice have higher susceptibility than female mice
in cardiovascular disease [45]. Fourthly, the clinical population was
Asia Han only and the sample size is relatively small. Finally, the mechanism responsible for gCTRP5 selective signaling (as full CTRP5 had
no significant effect) remains to be identified.
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